Skip to content

IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation

Currently, no standard of care exists in the adjuvant setting for hepatocellular carcinoma following resection or ablation with curative intent. Here we report the results of IMbrave050, a global, open-label, Phase 3, randomized study of atezolizumab + bevacizumab vs active surveillance in patients at high risk of disease recurrence following resection or ablation with curative intent.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Send Via Email

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

Leave Site Stay on Medically